Groupe Oncologie Radiotherapie Tete Et Cou

This Phase 3 trial is testing two new drug combinations—ivonescimab alone or with ligufalimab—against the standard treatment pembrolizumab (Keytruda) for people with advanced head and neck cancer that has come back or spread. The study will enroll about 780 participants to see if…

This study tests whether adding an immunotherapy drug (pucotenlimab) to a targeted therapy (MRG003) before standard chemoradiation can shrink tumors more effectively in people with advanced head and neck cancer. About 106 adults aged 18-75 with locally advanced squamous cell carc…